This $617,376 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to elucidate the timing and regulation of HIV-1 protease autoactivation, a critical process in the maturation of infectious HIV-1 particles. The research team at Emory University will utilize advanced imaging techniques, including FRET probes and correlative light-electron microscopy, to visualize...
This $1,617,200 federal Project Grant award, issued by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research program), supports research to investigate the immune microenvironments that impact HIV persistence and expression during antiretroviral therapy. The research aims to determine the location, phenotype, and microenvironment of HIV RNA-expressing cells in secondary lymphoid tissues of people with HIV on prolonged antiretroviral...
This $571,685 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at the University of Utah to investigate the biomechanical principles governing the assembly, release, and maturation of HIV virions. The key objectives are to: 1) analyze the effects of non-Gag HIV components on the stability of the immature viral lattice, and 2) determine how dynamics within the lattice drive activation...
This $502,861 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research on the role of the protein PCIF1 in regulating host-HIV interactions. The key objectives are to: 1) Define the dynamics and mapping of human N6,2'-O-dimethyladenosine (m6Am) RNA methylome in response to HIV infection and methamphetamine exposure; 2) Determine how HIV alters the m6Am methylome of host cells; and 3)...
This R21 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop a computational toolkit for systematically analyzing protein drug resistance mechanisms to enable the rational design of effective counter-strategies against HIV drug resistance. The $176,096 grant, awarded from August 1, 2024 to June 30, 2026, will support research at the University of Illinois to: 1) develop rigorous methods for...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $474,620 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF). The five-year grant, with a performance period from August 15, 2024 to July 31, 2029, will support research to comprehensively define the selective pressures on the HIV-1 capsid. Using a high-throughput mutagenesis approach, the project aims to identify...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop novel HIV capsid-targeting antivirals that can maintain activity against drug-resistant HIV strains. The $223,300 award, effective from January 17, 2025 to December 31, 2026, will fund the synthesis and characterization of antiviral compound analogs designed to target clinically...
This federal Project Grant award, valued at $136,350.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to understand how HIV-1 packages its RNA genome during virus assembly. The proposed studies aim to (1) identify the structural determinants and mechanism of the Gag polyprotein assembly on the viral RNA packaging signal, and (2) collect structural...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,157,123 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Childrens Hospital Medical Center in Cincinnati, Ohio. The grant will fund a project titled "Viral and Cellular Determinants of HIV-1 Assembly" that aims to define the host recycling pathways and cellular components essential for incorporation of the HIV envelope protein into viral particles. Key goals of the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports scientific research to understand HIV persistence and HIV-induced immune activation despite effective antiretroviral therapy (ART). The $872,684 award, with a performance period from June 2024 to May 2029, will utilize single-cell multi-omic approaches to profile the rare and heterogeneous HIV-infected cells and...
This $220,224 Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to computationally investigate three key morphological transitions in the HIV-1 life cycle - assembly and budding of the immature virion, maturation of the viral core, and uncoating - with a focus on the role of factors beyond the capsid domain proteins, including RNA, host cell factors, and potential therapeutics. The research will incorporate computational modeling techniques to better understand the physical and molecular mechanisms underlying these critical steps in the HIV-1 infection process. Findings from this work could aid in the design of future antiretroviral therapies targeting viral assembly, maturation, and uncoating. The award was made to the University of Chicago and will run from January 2025 through September 2027.